Igyxos’ IGX12 brings a fresh approach to infertility treatment, aiming to improve outcomes for both men and women.

Delve into Vandria's technology and its Alzheimer's candidate, VNA-318, the first mitophagy-based candidate in Alzheimer's in ...

A new wave of metabolic disease drugs beyond GLP-1 agonists is emerging to address the unmet needs of patients.

Discover six obesity deals made so far in 2025, with dealmaking activity in the field being largely dominated by big pharma companies.

While non-exhaustive, this list offers an overview of the year’s biotech events taking place around the world, aimed at partnering and connecting with decision makers in biopharma. If there is a ...

Research Triangle Park in North Carolina has emerged as one of the U.S’s most dynamic and rapidly expanding biotech hubs, home to a thriving ecosystem of established pharma companies, research ...

Discover the emergence of dual-payload ADCs and PDCs, which could mark a significant evolution in targeted therapeutics.

The need for change in Novo Nordisk’s operations became irrefutably clear in July, when the company named its new CEO, Maziar Mike Doustdar, and simultaneously issued a profit warning for its ...

Since the first biosimilar approval in Europe twenty years ago, biosimilars have provided 6.9 billion patient treatment days and now provide 12% of the total volume of biologic treatments in Europe.

First, let’s take a look at the private biotech investments in October 2025, breaking them down by value, location, funding type, and therapeutic subsector. While many companies raised impressive ...

Synthetic biology (SynBio) has stopped dividing itself by categories — red, yellow, green, blue, white — medicine, environment, agriculture, water, and industry —and is now united as one movement, ...